

Dear Sir / Madam,

Please find attached the Investors' Presentation for your ready reference.

Please bring the above information to the knowledge of investors at large.

The presentation is will also be uploaded on the website of the company.

Thanking You,

Yours faithfully, For, CADILA HEALTHCARE LIMITED

UPEN H. SHAH COMPANY SECRETARY



Cadila Healthcare Limited


Investor Presentation

June 2017



A Leading Pharmaceutical Company







Vertically Integrated Business Model with Presence Across The Pharma Value Chain



APIs	Generics and Niche Generics	Specialty and Branded Business ⁽¹⁾	Biologics and Vaccines	NCEs
 Selective backward integration Niche API supply to key clients ~200 scientists² 128 active DMFs filed with USFDA² 	 Increased focus on niche categories (Transdermal, Nasals, Modified Release Oral Solids, Topicals etc.) 650+ scientists Total 309 ANDAs filed (as of Mar 31, 2017) 80+ para IV filings Generating ~85% revenues from formulations business across India, U.S. and other markets 	 Focus on pain management, dermatology and oncology products Development of 505(b)(2) opportunities Acquisition of Sentynl Therapeutics Inc., specializing in pain management 	 Biologics: 18 biosimilars (pipeline and launched) and 7 novel products (pipeline) ² 8 launched in India; 2 in Emerging Markets Exemptia[™] (biosimilar of Adalimumab) in India 80+ scientists, Vaccines: 18 under development (including 6 where marketing authorization has been received) 4 vaccines launched 30+ scientists Dedicated, separate facilities for biologics and vaccines 	 NCEs: 4 NCEs (3 new and 1 existing for new indications)² 1st NCE in India developed in-house by the company: Lipaglyn® (Saroglitazar) 3 indications of Lipaglyn® approved for Phase II trials in US ~250 scientists Strong scientific advisory board Dedicated research facility



Key Business Segments






	Key Formulations Businesses	Other Businesses & Alliances	Emerging Businesses
Divisions	 India formulations #4 by value¹ 4.2% market share ¹ US formulations #9 by prescription volumes² ~3% market share ² Latin America Emerging Markets of Asia and Africa 	 EU Formulations Consumer Wellness Animal Health APIs JVs & alliances 	 Biologics Vaccines NCEs
Key Themes	 Sustainable and profitable growth Significant revenue contribution 	Growth potential in Wellness and Animal Health segments	 Innovative technology with high entry barriers for competition
In-House Capabilities serving as bedrock of organization	32 manufacturing facilities across India, US, Brazil and Germany Manufacturing	8 R&D sites across India, US and Italy ~1,200 scientists R&D Capabilities	Highly experienced and qualified management team



Track Record of Value Creation







- 1. FY07 and FY12 financials as per IGAAP; FY17 financials as per INDAS and hence not comparable
- 2. US\$ 1 = 64.5
- 3. Market capitalization is calculated by applying the closing price of the financial year

4. As of June 9, 2017



Key Business Segments






Our US Formulations Business

- #9 generics player in US (based on prescriptions) with a market share of ~3%¹
 - Among top 3 in 8 out of top 10 products marketed in US²
- Sale of generic oral solids and injectable products; ~90 products commercialized
- Recently received USFDA approval for generic version of Lialda® (Mesalamine Delayed Release 1.2 g)
- Strong product pipeline
 - 197 ANDAs pending approval (of which 75+ Para IV filings)
- Cost efficient manufacturing and supply chain
- Relationships with key wholesalers and retail pharmacy chains
- Acquired Sentynl Therapeutics Inc., a US based specialty pharmaceutical company, specializing in pain management segment in Fiscal 2017

Our US Formulation Sales







Strong Filing Track Record and Addition to Capabilities



Growing Focus on Complex Generics Business







Large ANDA Pipeline With Increasing Focus on Niche Filings




Approved ANDAs by Type

As on 31 Mar 2017

ANDA Pending Approval—Focus on Niche Segments

As on 31 Mar 2017






Strong Leadership in India Formulations Business



Leading Player in the \$13 Bn Market of India¹






- 2. As per AWACS MAT March 2017
- 3. FY15 financials as per IGAAP; FY16 and FY17 financials as per INDAS
- 4. Excludes ~1,400 managers
- 5. US\$ 1 = INR 64.5
- 6. Source: AWACS

Focus on Key Therapeutic Areas in India





Leadership positions (top 3) in Gynaecology, Respiratory, Pain Management, Cardiovascular, Dermatology and GI

Trademark acquisitions to fill the portfolio gaps – recently acquired trademarks from MSD in men's and women's health

Introduction of biologicals and vaccines products

In-licensing arrangements

Improving field force productivity



Represents Zydus' ranking in the promoted covered market

Other Growing Formulations Markets




Latin America		Emerging Markets		
			Emerging Markets in Asia and Africa	
Zydus Size ²	c.US\$ 38 MM	Zydus Size ²	c.US\$ 78 MM	
Zydus Growth	~12%	Zydus Growth	~6%	
 Two large pharmace 	eutical markets in Latin America	 Branded generics an 	d generic generics	
 Branded generics and generic generics 		One of the leading companies in several of these markets		
Brazil: 98 filings, 46 approvals, ~40 products being sold		Launched 2 biosimilars		
 Mexico: 40+ filings, 35+ approvals, 20+ products commercialized 		 Continue to expand geographical presence in select emerging markets 		
 Focused segments (Branded) – CVS, central nervous system, female healthcare, hepatology and nutraceuticals 		 Leveraging existing portfolio of India and other regulated markets 		



Other Businesses









Value Creation Through Win-win Alliances and Be a Partner of Choice

Zydus Takeda JV

- 50:50 JV with Takeda Pharmaceuticals
- Currently manufacturing complex high-end APIs of Takeda
- Commercial supply of 11 products

Zydus Hospira JV

- 50:50 contract manufacturing JV with Hospira¹ for cytotoxic injectable products
- State-of-the-art cytotoxic facility which is inspected by leading authorities like MHRA, USFDA, TGA etc.
- Manufactured ~17 products which are sold primarily in US and EU

Bayer Zydus JV

- 50:50 JV with Bayer
- Operates in female healthcare, metabolic disorders, diagnostics, CVS, anti-diabetics and oncology segments in India
- Leveraging strengths of Bayer's optimised product portfolio and Zydus' marketing and distribution capabilities
- JV scope covers launch of innovator products of Bayer in India

Other Alliances

- 26 ANDAs filed, 13 approved (for partners)
- Out-licensing deal with Abbott for supply of 24 products (with an option to include 39 additional products)
- Out-licensing and distribution arrangements for biosimilars in certain emerging markets like Turkey, Russia, Indonesia and Columbia





Manufacturing and Innovation



Strong Base of Cost Efficient and State-of-the-Art Manufacturing Facilities





17 facilities for formulations, 4 for API, 3 for vaccines, 3 for biologics, 3 for consumer wellness and 2 for animal health

Capabilities across platforms - Oral Solids, Controlled Substances, Injectables, Topicals, Lyophilized Injectable, Sprays and Transdermals


Focus on quality, efficiency and regulatory compliance



Key Focus Areas for R&D



R&D expenditure formed ~8%¹ of total operating revenues



Vaccines

NCEs

Capabilities in Complex Segments



Biologics

- 18 biosimilars (pipeline and launched) and 7 novel products (pipeline)
 - Launched 8 products in India and 2 in Emerging Market
 - Launched Exemptia[™] (biosimilar of Adalimumab) – 1st company in India¹
 - 4 products already in clinical development phase
 - Development of RabiMabs in collaboration with WHO
- Wide range of indications covered including oncology, nephrology, ophthalmology, infectious diseases, osteoporosis, inflammation

Vaccines

- Launched 4 products, received marketing authorizations for 6 other
 - First Indian company to launch indigenously developed and manufactured H1N1 vaccine – VaxiFlu-S¹
- 18 under development (including 6 where marketing authorization has been received)

NCEs

- Launched Lipaglyn[®] 1st NCE developed by the company, for 2 indications (Diabetic Dyslipidemia and Hypertriglyceridemia)
 - Phase III trials ongoing in India for 3 indications (Lipodystrophy, NASH², Type 2 Diabetes)
 - 3 indications approved for Phase II trials in US (NASH², PBC³ and Hypertriglyceridemia)
- 3 other NCE molecules under various stages of development
 - ZYH7 (Dyslipidemia)
 - ZYDPLA1 in US (Type 2 Diabetes)
 - ZYAN1 (Anemia)






Key Financials




Strong Financial Profile


















1. US\$1 = INR 64.5

2. FY15 financials as per IGAAP; FY16 and FY17 financials as per INDAS and hence not comparable

3. ROE = PAT / average of opening and closing net worth; ROCE = (Profit after tax + Finance cost net of tax) / average of opening (net worth + gross debt)

Strategies For The Future







Building Blocks For Our Strategy



Regulatory Compliance and Quality	 Focus on best in class manufacturing People training QUEST: Quality Excellence by Sustainable Transformation; Institutionalising a Culture of Quality
Operational Excellence	 PRISM – cost optimization program adopted in 2002 and institutionalised across the group SLIM - a Strategic, Lean and Integrated Manufacturing initiative
Innovate For Growth	 Continue to replenish generic pipeline in the US with profitable opportunities – move towards specialty In the branded generics / specialty markets of India and other emerging market to focus on additional growth from more advanced areas like biologics Continue to invest behind, innovate and commercialize opportunities in biologics, vaccines and NCEs Near term focus on emerging markets with longer term potential in developed markets
M&A	 Selective M&A Complimentary generic assets or technology platforms Specialty or branded assets Consolidation / leadership





Thank You

DISCLAIMER AND SAFE HARBOUR STATEMENT

THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF CADILA HEALTHCARE LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY").

The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.

This document is just a Presentation and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company's equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.

This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever.

